Background. During osteoblastic cell differentiation a subset of osteoblasts may be involved in many inmune functions such as phagocytosis and T cell activation. When osteoblasts are in contact with microorganisms and endoprosthetic materials, they perform immune functions in order to eliminate them. Some studies carried out in animal models have shown that NSAID reduce the proliferation capacity of bone forming cells, such as Indomethacin. However, its effects on other functional parameters of the osteoblast are not yet known.

Objectives: The aim of our work is studying the effect of Indomethacin and Diclofenac on the phacocytic capacity of human osteoblasts. The human osteosarcoma line MG-63 will be regarded as a study model.

Methods: Human osteoblasts (line MG-63) were treated with two different NSAID: Indomethacin and Diclofenac. A 10 ìM dose was used for both studies. The analysis of the phagocytic capacity was carried out by a cytometric technique. The target particles were little fluorescent latex bears.

Results: Our results show that the Diclofenac treatment of the MG-63 line reduces in a significant way the percentage of cells having a phagocytic capacity (p< 0.004). An important reduction of the number of particles per cellular unit was also detected (p< 0.044). However, the Indomethacin treatment did not alter significantly such functional capacity. Given the clinical repercussions of these drugs for a possible bone tissue treatment, these results reveal the need of a wider analysis of the NSAID effects on the different parameters of bone-forming cells.

Conclusions: The treatment of the MG-63 line with Diclofenac decreased the phagocytic capacity. Non effect was observed by treatment with Indomethacin.

Back to the Scientific Groups Program
Back to the IADR Pan European Federation 2006 (September 13-16, 2006)

Top Level Search